Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

January 2014 - FRMC

01/21/2014

Kerri Fitzgerald

Kerri Fitzgerald
San Antonio—While electronic prescribing (e-prescribing) has been widely recommended for its ability to reduce medication errors, especially transcription errors; however, according to recent study literature, the rates of e-prescribing...
San Antonio—While electronic prescribing (e-prescribing) has been widely recommended for its ability to reduce medication errors, especially transcription errors; however, according to recent study literature, the rates of e-prescribing...
San Antonio—While electronic...
01/21/2014
First Report Managed Care
01/21/2014

Tim Casey

Tim Casey
When handling specialty drugs, physicians typically purchase the medications directly from distributors, administer them to patients, and then bill payers.
When handling specialty drugs, physicians typically purchase the medications directly from distributors, administer them to patients, and then bill payers.
When handling specialty drugs,...
01/21/2014
First Report Managed Care
01/21/2014

Tim Casey

Tim Casey
Dallas—Stenting added to medical therapy did not reduce the rate of major cardiovascular and renal events compared with medical therapy alone in patients with atherosclerotic renal artery stenosis and hypertension or chronic kidney disease,...
Dallas—Stenting added to medical therapy did not reduce the rate of major cardiovascular and renal events compared with medical therapy alone in patients with atherosclerotic renal artery stenosis and hypertension or chronic kidney disease,...
Dallas—Stenting added to medical...
01/21/2014
First Report Managed Care
01/21/2014

Tim Casey

Tim Casey
Dallas—A randomized, double-blind trial that included patients with atrial fibrillation (AF) found that 2, once-daily doses of edoxaban were noninferior to warfarin in preventing strokes or systemic embolic events. Patients who received...
Dallas—A randomized, double-blind trial that included patients with atrial fibrillation (AF) found that 2, once-daily doses of edoxaban were noninferior to warfarin in preventing strokes or systemic embolic events. Patients who received...
Dallas—A randomized,...
01/21/2014
First Report Managed Care
01/21/2014

Tim Casey

Tim Casey
Dallas—Patients with peripheral arterial disease (PAD) and intermittent claudication who underwent endovascular revascularization and supervised exercise therapy had a significant improvement in walking distance and quality of life compared...
Dallas—Patients with peripheral arterial disease (PAD) and intermittent claudication who underwent endovascular revascularization and supervised exercise therapy had a significant improvement in walking distance and quality of life compared...
Dallas—Patients with peripheral...
01/21/2014
First Report Managed Care
01/21/2014

Tim Casey

Tim Casey
Dallas—A prospective, multi-center, single-blind, randomized trial found that patients with paroxysmal, symptomatic, drug-refractory atrial fibrillation (AF) had no significant difference in freedom from AF or atrial tachyarrhythmias after 1...
Dallas—A prospective, multi-center, single-blind, randomized trial found that patients with paroxysmal, symptomatic, drug-refractory atrial fibrillation (AF) had no significant difference in freedom from AF or atrial tachyarrhythmias after 1...
Dallas—A prospective,...
01/21/2014
First Report Managed Care
01/21/2014

Kerri Fitzgerald

Kerri Fitzgerald
Dallas—Previous clinical trials have found that lowering blood pressure (BP) reduces the risk of stroke in hypertensive and normotensive patients with a history of stroke or transient ischemic attack. However, the effect of antihypertensive...
Dallas—Previous clinical trials have found that lowering blood pressure (BP) reduces the risk of stroke in hypertensive and normotensive patients with a history of stroke or transient ischemic attack. However, the effect of antihypertensive...
Dallas—Previous clinical trials...
01/21/2014
First Report Managed Care
01/21/2014

Tim Casey

Tim Casey
New Orleans—After at least a year of treatment with ibrutinib, more than 80% of patients with treatment-naïve or relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL) had a partial or complete response,...
New Orleans—After at least a year of treatment with ibrutinib, more than 80% of patients with treatment-naïve or relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL) had a partial or complete response,...
New Orleans—After at least a...
01/21/2014
First Report Managed Care

Department

Conference Insider
01/21/2014

Kerri Fitzgerald

Kerri Fitzgerald
San Antonio—Prophylaxis with factor VII or IX has been shown to reduce bleeding episodes for patients with hemophilia A and B; however, a recent study finds that most individuals with severe hemophilia are not adherent to a routine...
San Antonio—Prophylaxis with factor VII or IX has been shown to reduce bleeding episodes for patients with hemophilia A and B; however, a recent study finds that most individuals with severe hemophilia are not adherent to a routine...
San Antonio—Prophylaxis with...
01/21/2014
First Report Managed Care
Conference Insider
01/21/2014

Tim Casey

Tim Casey
Dallas—After a year of treatment, patients with hypercholesterolemia who received evolocumab plus the standard of care had a mean reduction of 50% in low-density lipoprotein (LDL) cholesterol compared with a group that took optimal standard...
Dallas—After a year of treatment, patients with hypercholesterolemia who received evolocumab plus the standard of care had a mean reduction of 50% in low-density lipoprotein (LDL) cholesterol compared with a group that took optimal standard...
Dallas—After a year of...
01/21/2014
First Report Managed Care

Advertisement

Advertisement

Advertisement